Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma
International Journal of Immunopathology and Pharmacology · 2024
DOI: 10.1177/03946320241250294 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2024. Verfasst von Menha Swellam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza, Egypt. Hauptthemen laut MEDLINE: DNA Methylation, Glioblastoma, Tumor Suppressor Proteins, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science, Technology and Innovation Funding Authority.
Abstract (Originalsprache)
Objectives
Gliobalstoma is the most common primary brain tumor in adults with an extensive genetic and transcriptional heterogeneity, still identification of the role of DNA methylation, as one of epigenetic alterations, is emerged. Authors aimed to study the clinical role of N-myc downstream-regulated gene 2 (NDRG2) –based methylation among GBM patients versus benign neurological diseases (BND), investigate its prognostic role and its relation with survival outcomes.
Methods
A total of 78 FFPE specimens were recruited as follows: GBM ( n = 58) and BND ( n = 20) then analyzed for NDRG2 methylation using Methyl II quantitative PCR system. The sensitivity and specificity of methylation was detected using receiver operating characteristic (ROC) curve and the relation with clinicopathological criteria for GBM and response to treatment were studied. Survival patterns; progression free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier analyses.
Results
Mean methylation NDRG2 level was significantly increased in GBM patients as compared to BND and its sensitivity and specificity were 96.55% and 95%, respectively with area under curve (AUC) equals 0.973. Among the clinical characteristic factors, mean methylation level reported significant difference with ECOG and tumor site. Survival out comes revealed that NDRG2 methylation increased with worse PFS and OS at significant level (long rank test X 2 = 13.3, p < .0001; and X 2 = 7.1, p = .008, respectively).
Conclusion
Current findings highlight the importance of studying DNA methylation of NDRG2 as a key factor to understand the role of epigenetic alterations in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza, Egypt.
- High Throughput Molecular and Genetic laboratory, Central Laboratories Network and the Centers of Excellence, National Research Centre, Dokki, Giza, Egypt.
- CSO at Omnicsense, Giza, Egypt.
- Molecular Pathology Lab, Children Cancer Hospital, Giza, Egypt.
- Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Menha Swellam
Förderung
- Science, Technology and Innovation Funding Authority
Zitieren
APA
Swellam, M., Khalifa, M. K., Nageeb, A. M., Ezz El-Arab, L., El-Mahdy, M., El-Bahy, K., & Sayed Mahmoud, M. (2024). Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320241250294
Vancouver
Swellam M, Khalifa MK, Nageeb AM, Ezz El-Arab L, El-Mahdy M, El-Bahy K, et al. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma. International Journal of Immunopathology and Pharmacology. 2024. doi:10.1177/03946320241250294
BibTeX
@article{Swellam2024,
author = {Swellam, Menha and Khalifa, Mohamed K and Nageeb, Amira M and Ezz El-Arab, Lobna and El-Mahdy, Manal and El-Bahy, Khaled and Sayed Mahmoud, Magda},
title = {Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2024},
doi = {10.1177/03946320241250294}
}
EUVIMED